-

04:57:09 PM

NMTR Stock News

NMTR - 9 Meters Biopharma Inc

06/21/22 8:00 AM

Nasdaq : NMTR

clinical trial

9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a

RHEA-AI

neutral

06/13/22 4:35 PM

Nasdaq : NMTR

conferences

9 Meters Biopharma to Participate in the 2022 BIO International Convention

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced the Company's participation in the 2022 BIO International Convention on June 13 - 16, 2022, in

RHEA-AI

neutral

05/19/22 8:00 AM

Nasdaq : NMTR

9 Meters Biopharma to Exhibit at Digestive Disease Week 2022

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced that the company will host an exhibit at Digestive Disease Week (DDW) which takes place May

RHEA-AI

neutral

05/18/22 8:00 AM

Nasdaq : NMTR

clinical trial

9 Meters Biopharma Presents Preclinical Data at the 2022 American Thoracic Society International Conference on the Use of Larazotide in Idiopathic Pulmonary Fibrosis

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced that Matthew Bryant, PharmD, Vice President of Medical Affairs at 9 Meters, delivered a poster

RHEA-AI

neutral

05/16/22 7:00 AM

Nasdaq : NMTR

earnings

9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2022

RHEA-AI

neutral

05/05/22 8:00 AM

Nasdaq : NMTR

conferences

9 Meters Biopharma to Present at the H.C. Wainwright Global Investment Conference and the LifeSci Partners Immunology & Inflammation Symposium

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that John Temperato, President & Chief Executive Officer of 9 Meters, will present at the

RHEA-AI

neutral

04/20/22 9:00 AM

Nasdaq : NMTR

clinical trial

9 Meters Biopharma and Celiac.com Announce Collaboration to Support Clinical Trial Enrollment in 9 Meter's Phase 3 Study for Celiac Disease

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, and Celiac.com, a news, information, and support website for those on a gluten-free

RHEA-AI

neutral

04/13/22 7:00 AM

Nasdaq : NMTR

9 Meters Biopharma Announces Allowance of Patent for Anti-GIP Monoclonal Antibody NM-136 for the Treatment of Serious Metabolic Conditions

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that the Company has received notice from the United States Patent and Trademark Office

RHEA-AI

neutral

03/23/22 7:00 AM

Nasdaq : NMTR

earnings

9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2021

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial

RHEA-AI

positive

03/21/22 8:00 AM

Nasdaq : NMTR

conferences

9 Meters Biopharma to Present at the Maxim Group 2022 Virtual Growth Conference

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that John Temperato, President & Chief Executive Officer of 9 Meters, will present at the

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next